Detalles de la búsqueda
1.
M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
Clin Chem Lab Med
; 62(3): 540-550, 2024 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37823394
2.
An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients.
Clin Chem Lab Med
; 2024 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38872409
3.
N-linked glycosylation of the M-protein variable region: glycoproteogenomics reveals a new layer of personalized complexity in multiple myeloma.
Clin Chem Lab Med
; 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38332688
4.
Advances in minimal residual disease monitoring in multiple myeloma.
Crit Rev Clin Lab Sci
; 60(7): 518-534, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37232394
5.
Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.
Cytotherapy
; 23(1): 46-56, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32948458
6.
Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
Transpl Immunol
; 57: 101209, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31207283
7.
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
Blood Cancer J
; 13(1): 30, 2023 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828828
Resultados
1 -
7
de 7
1
Próxima >
>>